Study of the Antiviral Mechanism of Cytovir®-3 Against Respiratory Viruses In Vitro

Background. Modern clinical practice often excludes the possibility of differential diagnostics for acute respiratory viral infection pathogens and identification of a specific viral pathogen. In this regard, it is important to search for drugs with a broad spectrum of activity against pathogens of acute respiratory viral infections. The aim of the study was to assess the antiviral activity of the drug Cytovir®-3 in vitro against the cytopathogenic effect of human adenovirus. Material and methods. The antiviral effect of the drug Cytovir®-3 in comparison with the drug Umifenovir against human adenovirus type 5 was studied on Vero cell culture. The drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (therapeutic regimen) infection of the cell culture with the virus. The working concentration range for the studied drugs was determined based on the 50% cytotoxic concentration values, calculated based on the results of the microtetrazolium (MTT) assay. Results and discussion. The drug Cytovir®-3 in two application regimens (therapeutic or prophylactic) demonstrated antiviral efficacy in vitro against human adenovirus in the non-toxic range (0-631 µg/ml) regardless of the application scheme (therapeutic or prophylactic). Conclusion. The in vitro antiviral activity of the drug Cytovir®-3 against human adenovirus has been proven. Moreover, in all series of experiments, Cytovir®-3 had a selectivity index comparable to that of the reference drug Umifenovir.

1. Baker R. E., Mahmud A. S., Miller I. F., Rajeev M., Rasambainarivo F., Rice B. L. et al. Infection disease in an era of global change. Nat Rev Microbiol. 2022; 20 (4): 193–205. doi: 10.1038/s41579-021-00639-z.

2. Клинические рекомендации: Острые респираторные вирусные инфекции (ОРВИ) у взрослых — 2021–2022–2023 (15.02.2022). https://recipture.ru/recommend/LOR/ORVI1v.pdf

3. Liu Y., Wang H., Yang J., Zeng J., Sun G. M. Virome of respiratory secretion from children with unknown etiological acute respiratory disease revealed recombinant human parechovirus and other significant viruses. Virol J. 2021; 18 (1): 122. doi: 10.1186/s12985-021-01586-0.

4. Александрович Ю. С., Козлова Е. М., Новопольцева Е. Г., Новопольцев Д. Е. Острые респираторные инфекции у детей. Осложнения и жизнеугрожающие состояния: Учебное пособие для врачей. СПб.: СПбГПМУ; 2021.

5. Клинические рекомендации: Грипп у взрослых — 2022–2023–2024. http://disuria.ru/_ld/12/1263_kr22J9J10J11MZ.pdf.

6. Hilleman M. R., Werner J. H. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med.1954; 85: 183–188. doi: 10.3181/00379727-85-20825.

7. Rowe W. P., Huebner R. J., Gilmore L. K., Parrott R. H., Ward T. G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953; 84: 570–573. doi: 10.3181/00379727-84-20714.

8. Zhang D., Chen Y., Shi T., Fan H., Tian X., Zhou R., Huang L., Yang D., Lu G. Severe pneumonia caused by human adenovirus type 55 in children. Front Pediatr. 2022; 10: 1002052. doi: 10.3389/fped.2022.1002052.

9. Zhang W., Huang L. Genome analysis of a novel recombinant human adenovirus type 1 in China. Sci Rep. 2019; 9 (1): 4298. doi: 10.1038/s41598-018-37756-4.

10. Cai R., Mao N., Dai J., Xiang X., Xu J., Ma Y. et al. Genetic variability of human adenovirus type 7 circulating in mainland China. PLoS ONE. 2020; 15 (4): e0232092. doi: 10.1371/journal.pone.0232092.

11. Lynch J. P., Kajon A. E. Adenovirus: epidemiology, global spread of novel types, and approach to treatment. Semin Respir Crit Care Med. 2021; 42: 800–821. doi: 10.1055/s-0041-1733802.

12. Clementi N., Ghosh S., De Santis M., Castelli M., Criscuolo E., Zanoni I., Clementi M., Mancini N. Viral respiratory pathogens and lung injury. Clin Microbiol Rev. 2021. Mar 31; 34 (3): e00103–20. doi: 10.1128/CMR.00103-20.

13. Яцышина С. Б., Самчук В. В., Васильев В. В., Агеева М. Р., Воробьева Н. С., Савочкина Ю. А., Буланенкот В. П., Шипулин Г. А., Малеев В. В. Аденовирусная пневмония с летальным исходом у взрослых. Терапевтический архив. 2014; 11: 56–59.

14. Hierhozler, J.C. Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992; 5, 262–274. doi: 10.1128/CMR.5.3.262.

15. Chen Y., Lin T., Wang C. B., Liang W. L., Lian G. W., Zanin M. et al. Human adenovirus (HAdV) infection in children with acute respiratory tract infections in Guangzhou, China, 2010–2021: a molecular epidemiology study. World J Pediatr. 2022; 18 (8): 545–52. doi: 10.1007/s12519-022-00590-w.

16. Shieh W.-J. Human adenovirus infections in pediatric population — an update on clinico–pathologic correlation. Biomedical J. 2022; 45 (1): 38–49. doi: 10.1016/j.bj.2021.08.009.

17. Russell K. L., Hawksworth A. W., Ryan M. A., Strickler J., Irvine M., Hansen C. J., Gray G. C., Gaydos J. C. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. Vaccine. 2006; 24 (15): 2835–42. doi: 10.1016/j.vaccine.2005.12.062.

18. Abed Y., Boivin G. Treatment of respiratory virus infections. Antiviral Res. 2006 Jun; 70 (2): 1–16. doi: 10.1016/j.antiviral.2006.01.006.

19. Das А., Trousdale М. D., Ren S., Lien Е. J. Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res. 1999; 44 (3): 201–208. doi: 10.1016/s0166-3542(99)00070-4.

20. De Clercq Е., Sakuma Т., Baba М., Pauwels R., Balzarini J., Rosenberg I., Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Аntiviral Res. 1987; 8 (5-6): 261–272. doi: 10.1016/s0166-3542(87)80004-9.

21. Arav-Boger R., Echavarria М., Forman М., Charache Р., Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000; 19 (11): 1097–1100. doi: 10.1097/00006454-200011000-00016.

22. Shetty А. К., GLns Н. А., So S., Millan М. T., Arvin А. М., Gutierrez К. M. Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonol 2000; 29 (1): 69–73. doi: 10.1002/(sici)1099-0496(200001)29:1<64::aid-ppul11>3.0.co;2-d.

23. Gavin P. J., Katz B. Z. Intravenous Ribavirin Treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110 (1 Pt 1): e9. doi: 10.1542/peds.110.1.e9.

24. Bordigoni Р., Carret А. S., Venard V., Witz F., Lе Faou А. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32 (9): 1290–1297. doi: 10.1086/319984. Epub 2001 Apr 10.

25. La Rosa A. M., Champlin R. Е., Mirza М., Gajewski J., Giralt S., Rolston K. V. et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32 (6): 871–876. doi: 10.1086/319352. Epub 2001 Mar 9.

26. Trousdale М. D., Goldschmidt Р. L., Nobre G. L. R. Activity of ganciclovir against human adenovirus type 5 infection in cell culture and cotton rat eyes. Cornea. 1994; 13 (5): 435–439. doi: 10.1097/00003226-199409000-00011.

27. Chen F. Е., Liang R. Н., Lo J. Y., Yuen К. Y., Chan T. К., Peiris М. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant 1997; 20 (11): 997–999. doi: 10.1038/sj.bmt.1700997.

28. Ison M. G. Respiratory viral infections in the immunocompromised. Curr Opin Pulm Med. 2022; 28 (3): 205–210. doi: 10.1097/MCP.00000000-00000858.

29. Hillenkamp J., Reinhard Т, Ross R. S., Böhringer D., Cartsburg O., Roggendorf M. et al. The effect of cidofovir 1% with and without cyclosporin A 1% as а topical treatment of acute adenoviral kerato-conjunctivitis: а controlled clinical pilot study. Ophtalmology 2002; 109 (5): 845–850. doi: 10.1016/s0161-6420(02)00992-2.

30. Hoffman J. А., Shah А. J., Ross L. А., Карооr N. Adenoviral infections and а prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7 (7): 388–394. doi: 10.1053/bbmt.2001.v7.pm11529489.

31. Romanowski E. G., Gordon Y. J., Araullo-Cruz T., Yates K. A., Kinchington P. R. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest Ophtalmol Vis Sci. 2001; 42 (8): 1812–1815.

32. Romanowski E. G., Yates К. А., Gordon Y. J. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001; 52 (3): 275–280. doi: 10.1016/s0166-3542(01)00166-8.

33. Gordon Y. J., Naesens L., DeClercq E., Maudgal P. C . , Veckeneer M. The treatment of adenoviral conjunctivitis with topical cidofovir. Cornea. 1996; 15 (5): 546. doi: 10.1097/00003226-199609000-00018.

34. Hitchcock M. J. M., Jaffe H. S., Martin J. C., Stagg R. J. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir Chem Chemother. 1996; 7 (3): 115–127. doi: https://doi.org/10.1177/095632029600700301.

35. Safrin S., Cherrington J., Joffe H. S. Cidofovir. Review of current and potential clinical uses. Adv Exp Med Biol. 1999; 458: 111–120.

36. Coca S., Perazella M. A. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002; 324 (6): 342–344. doi: 10.1097/00000441-200212000-00011.

37. Rautenschlein S., Miller R. L., Sharma J. M. The inhibitory effect of the imidazoquinolinamine S-28828 on the pathogenesis of a type II adenovirus in turkeys. Antiviral Res. 2000; 46 (3): 195–205. doi: 10.1016/s0166-3542-(00)00086-3.

38. Mentel R., Kinder М., Wegner U., Janta-Lipinski М., Matthes Е. Inhibitory activity of 3-fluoro-2-deoxythymidine and related nucleoside analogues aGLinst adenoviruses in vitrо. Antiviral Res. 1997; 34 (3): 113–119. doi: 10.1016/s0166-3542(97)01029-2.

39. Weber J. M., Ruzindana-Umunyana A., Imbeault L., Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res. 2003; 58 (2): 167–173. doi: 10.1016/s0166-3542(02)00212-7.

40. Kaneko Н., Kato К., Mori S., Shigеtа S. Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res. 2001; 52 (3): 281–288. doi: 10.1016/s0166-3542(01)00167-x.

41. Zarubaev V. V., Slita A. V., Krivitskaya V. Z., Sirotkin A. K., Kovalenko A. L., Chatterjee N. K. Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antiviral Res. 2003; 58 (2): 131–137. doi: 10.1016/s0166-3542(02)00193-6.

42. Naesens L., Lenaerts L., Andrei G., Snoeck R., Van Beers D., Holy A., Balzarini J., DeClercq E. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother. 2005; 49: 1010–1016. doi: 10.1128/AAC.49.3.1010-1016.2005.

43. Alexeeva I., Dyachenko N., Nosach L., Zhovnovataya V., Rybalko S., Lozitskaya R., Fedchuk A., Lozitsky V., Gridina T., Shalamay A., Palchikovskaja-MaudgalL., Povnitsa O. 6-azacytidine–compound with wide spectrum of antiviral activity. Nucleosides Nucleotides Nucleic Acids. 2001 Apr–Jul; 20 (4–7): 1147–52. doi: 10.1081/NCN-100002508.

44. Zarubaev V. V., Slita A. V., Sukhinin V. P., Nosach L. N., Dyachenko N. S., Povnitsa O. Y., Zhovnovataya V. L., Alexeeva I. V., Palchikovskaya L. I. Effect of 6-azacytidine on the course of experimental adenoviral infection in newborn Syrian hamsters. J Chemother. 2007 Feb; 19 (1): 44–51. doi: 10.1179/joc.2007.19.1.44.

45. Mirmojarabian S., Karimi A., Lorigooini Z., Javadi-Farsani F., Soltani A., Moradi M. T. Phytochemical properties and antiviral effect of green tea (Camellia sinensis) extract on adenovirus in vitro. Journal of Shahrekord University of Medical Sciences. 2022; 24 (3): 104–110. doi: 10.34172/jsums.2022.17.

46. Zhang Y., Schneider R. J. Adenovirus inhibition of cellular protein synthesis and the specific translation of late viral mRNAs. Seminars in Virology. 1993; 4 (4): 229–236. doi: https://doi.org/10.1006/smvy.1993.1019.

47. Zhang W., Liu F., Liang E., Zhang L. Evolution of treatment modalities for disseminated HAdV infection in neonates. Pediatrics. 2024; 154 (4): e2024066677. doi: 10.1542/peds.2024-066677.

48. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65 (1-2): 55–63. doi: 10.1016/0022-1759(83)90303-4.